Publication | Closed Access

Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation

InflammationCytokineAnti-inflammatoryMedicineVivo Anti-inflammatory EfficacyImmunologyTumor ImmunityImmune RegulationHumoral ImmunityImmunotherapeuticsInnate ImmunityImmune FunctionNf-κb ActivationImmunotherapyPharmacologyInflammatory DiseaseIbrutinib-based Btk Protacs